151 related articles for article (PubMed ID: 38569863)
1. [Successful polatuzumab vedotin and rituximab therapy for post-CAR-T relapse of diffuse large B-cell lymphoma].
Kushida T; Hirosawa M; Goto M; Seike Y; Kitamura N; Nakanishi T; Tanaka A; Higashi T; Morimoto H; Tsukada J
Rinsho Ketsueki; 2024; 65(3):180-182. PubMed ID: 38569863
[TBL] [Abstract][Full Text] [Related]
2. An evaluation of polatuzumab vedotin for the treatment of patients with diffuse large B-cell lymphoma.
Walji M; Assouline S
Expert Rev Hematol; 2020 Sep; 13(9):933-942. PubMed ID: 32700586
[TBL] [Abstract][Full Text] [Related]
3. [Polatuzumab vedotin, bendamustine, and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma, including the outcome as a bridging treatment to CAR-T cell therapy or allogeneic hematopoietic stem cell transplant].
Morita Y; Yagi Y; Kanemasa Y; Sasaki Y; Ishimine K; Hayashi Y; Mino M; Ohigashi A; Tamura T; Nakamura S; Okuya T; Shimizuguchi T; Shingai N; Toya T; Shimizu H; Najima Y; Kobayashi T; Haraguchi K; Doki N; Okuyama Y; Ohashi K; Shimoyama T
Rinsho Ketsueki; 2023; 64(7):586-595. PubMed ID: 37544717
[TBL] [Abstract][Full Text] [Related]
4. Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.
Palanca-Wessels MC; Czuczman M; Salles G; Assouline S; Sehn LH; Flinn I; Patel MR; Sangha R; Hagenbeek A; Advani R; Tilly H; Casasnovas O; Press OW; Yalamanchili S; Kahn R; Dere RC; Lu D; Jones S; Jones C; Chu YW; Morschhauser F
Lancet Oncol; 2015 Jun; 16(6):704-15. PubMed ID: 25925619
[TBL] [Abstract][Full Text] [Related]
5. Polatuzumab vedotin plus bendamustine and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma in the real world.
Vodicka P; Benesova K; Janikova A; Prochazka V; Belada D; Mocikova H; Steinerova K; Duras J; Karban J; Hanackova V; Sykorova A; Obr A; Trneny M
Eur J Haematol; 2022 Aug; 109(2):162-165. PubMed ID: 35502609
[TBL] [Abstract][Full Text] [Related]
6. Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma.
Malecek MK; Watkins MP; Bartlett NL
Expert Opin Biol Ther; 2021 Jul; 21(7):831-839. PubMed ID: 32500753
[TBL] [Abstract][Full Text] [Related]
7. Polatuzumab vedotin to treat relapsed or refractory diffuse large B-cell lymphoma, in combination with bendamustine plus rituximab.
Amaya ML; Jimeno A; Kamdar M
Drugs Today (Barc); 2020 Apr; 56(4):287-294. PubMed ID: 32309823
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness Analysis of Frontline Polatuzumab-Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone and/or Second-Line Chimeric Antigen Receptor T-Cell Therapy Versus Standard of Care for Treatment of Patients With Intermediate- to High-Risk Diffuse Large B-Cell Lymphoma.
Vijenthira A; Kuruvilla J; Crump M; Jain M; Prica A
J Clin Oncol; 2023 Mar; 41(8):1577-1589. PubMed ID: 36315922
[TBL] [Abstract][Full Text] [Related]
9. Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b-2 study.
Tilly H; Morschhauser F; Bartlett NL; Mehta A; Salles G; Haioun C; Munoz J; Chen AI; Kolibaba K; Lu D; Yan M; Penuel E; Hirata J; Lee C; Sharman JP
Lancet Oncol; 2019 Jul; 20(7):998-1010. PubMed ID: 31101489
[TBL] [Abstract][Full Text] [Related]
10. [Current status and future prospects of diffuse large B-cell lymphoma treatment].
Yamaguchi M
Rinsho Ketsueki; 2022; 63(9):1126-1134. PubMed ID: 36198538
[TBL] [Abstract][Full Text] [Related]
11. Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
Abrisqueta P; González-Barca E; Panizo C; Pérez JMA; Miall F; Bastos-Oreiro M; Triguero A; Banerjee L; McMillan A; Seymour E; Hirata J; de Guzman J; Sharma S; Jin HY; Musick L; Diefenbach C
Lancet Haematol; 2024 Feb; 11(2):e136-e146. PubMed ID: 38190832
[TBL] [Abstract][Full Text] [Related]
12. Treatment strategies for patients with diffuse large B-cell lymphoma.
Poletto S; Novo M; Paruzzo L; Frascione PMM; Vitolo U
Cancer Treat Rev; 2022 Nov; 110():102443. PubMed ID: 35933930
[TBL] [Abstract][Full Text] [Related]
13. RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma.
Nowakowski GS; Yoon DH; Mondello P; Joffe E; Peters A; Fleury I; Greil R; Ku M; Marks R; Kim K; Zinzani PL; Trotman J; Sabatelli L; Waltl EE; Winderlich M; Sporchia A; Kurukulasuriya NC; Cordoba R; Hess G; Salles G
Ann Hematol; 2023 Jul; 102(7):1773-1787. PubMed ID: 37171597
[TBL] [Abstract][Full Text] [Related]
14. Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Sehn LH; Herrera AF; Flowers CR; Kamdar MK; McMillan A; Hertzberg M; Assouline S; Kim TM; Kim WS; Ozcan M; Hirata J; Penuel E; Paulson JN; Cheng J; Ku G; Matasar MJ
J Clin Oncol; 2020 Jan; 38(2):155-165. PubMed ID: 31693429
[TBL] [Abstract][Full Text] [Related]
15. Polatuzumab vedotin: an investigational anti-CD79b antibody drug conjugate for the treatment of diffuse large B-cell lymphoma.
Bourbon E; Salles G
Expert Opin Investig Drugs; 2020 Oct; 29(10):1079-1088. PubMed ID: 32700972
[TBL] [Abstract][Full Text] [Related]
16. A multicenter retrospective study of polatuzumab vedotin in patients with large B-cell lymphoma after CAR T-cell therapy.
Gouni S; Rosenthal AC; Crombie JL; Ip A; Kamdar MK; Hess B; Feng L; Watson G; Ayers A; Neelapu SS; Khurana A; Lin Y; Iqbal M; Merryman RW; Strati P
Blood Adv; 2022 May; 6(9):2757-2762. PubMed ID: 35240681
[TBL] [Abstract][Full Text] [Related]
17. Polatuzumab Vedotin: a New Target for B Cell Malignancies.
Choi Y; Diefenbach CS
Curr Hematol Malig Rep; 2020 Apr; 15(2):125-129. PubMed ID: 32172360
[TBL] [Abstract][Full Text] [Related]
18. Polatuzumab vedotin in relapsed / refractory aggressive B-cell lymphoma.
Varma G; Wang J; Diefenbach C
Expert Rev Anticancer Ther; 2022 Aug; 22(8):795-803. PubMed ID: 35726803
[TBL] [Abstract][Full Text] [Related]
19. Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma.
Dere RC; Beardsley RL; Lu D; Lu T; Ku GH; Man G; Nguyen V; Kaur S
Front Immunol; 2023; 14():1119510. PubMed ID: 37063860
[TBL] [Abstract][Full Text] [Related]
20. A phase 2 study of polatuzumab vedotin + bendamustine + rituximab in relapsed/refractory diffuse large B-cell lymphoma.
Terui Y; Rai S; Izutsu K; Yamaguchi M; Takizawa J; Kuroda J; Ishikawa T; Kato K; Suehiro Y; Fukuhara N; Ohmine K; Goto H; Yamamoto K; Kanemura N; Ueda Y; Ishizawa K; Kumagai K; Kawasaki A; Saito T; Hashizume M; Shibayama H
Cancer Sci; 2021 Jul; 112(7):2845-2854. PubMed ID: 33942442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]